|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Jeb_Keiper
|
|
gptkbp:collaboratedWith
|
gptkb:Gilead_Sciences
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:focusesOn
|
immunology
oncology
drug discovery
small molecule therapeutics
|
|
gptkbp:foundedYear
|
2009
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nimbus Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investor
|
gptkb:Lightstone_Ventures
gptkb:RA_Capital_Management
gptkb:Bill_Gates
gptkb:Polaris_Partners
gptkb:Pfizer_Ventures
gptkb:SR_One
gptkb:Atlas_Venture
gptkb:Canaan_Partners
|
|
gptkbp:notableProduct
|
gptkb:NDI-034858
NDI-3512
|
|
gptkbp:numberOfEmployees
|
100-200 (as of 2023)
|
|
gptkbp:openToPublic
|
gptkb:public_company
|
|
gptkbp:platform
|
computational chemistry
structure-based drug design
|
|
gptkbp:soldAssetTo
|
gptkb:Celgene
gptkb:Gilead_Sciences
|
|
gptkbp:website
|
https://www.nimbustx.com/
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Alexandria_Venture_Investments
gptkb:Mark_Leschly
gptkb:David_Grayzel
|
|
gptkbp:bfsLayer
|
6
|